OBJECTIVES: To assess the yearly frequency of ranibizumab injections for the treatment of wet Age-Related Macular Degeneration (wAMD ) in two large Canadian public drug plans: Ontario Public Drug Program (OPDP) and Régie de l’assurance-maladie du Québec (RAMQ). METHODS: Pharmastat database (IMS Health Canada Inc.) was used to assess the mean annual number of ranibizumab injections for wAMD patients covered by the OPDP or RAMQ drug plans (1 injection was defined as 1 claim).  Only wAMD treatment-naïve patients who had at least 6 months claims history were included, and the index date was defined as the date of the first ranibizumab claim.  The analysis looked at patients (by month) from Jan 2009 to March 2012 and tracked the mean number of claims during the patient's first, second, and third year of ranibizumab therapy. RESULTS: For the OPDP, the mean number of ranibizumab injections was 6.0, 5.2, and 5.1 for year 1 (N=15,367), year 2 (N=8,514), and year 3 (N=2,090), respectively. For the RAMQ, the mean number of injections was 5.4, 4.7, and 5.1 for year 1 (N=2,453), year 2 (N=1,293), and year 3 (N=302), respectively.  CONCLUSIONS: These results suggest that many Ontario and Quebec retina specialists and ophthalmologists adopted an individualized ranibizumab treatment regimen to manage their patients’ wAMD. The annual frequency of ranibizumab injections for OPDP and RAMQ was similar to that observed in clinical trials using monthly follow-up with clearly defined retreatment criteria.  In addition, these results provide information on the real-world utilization of ranibizumab in wAMD for up to three years of treatment. The analyses, conclusions, opinions and statements expressed are those of Novartis Pharmaceuticals Canada Inc., and not those of IMS Health Canada Inc.